Project Details
Description
Protocol #28821: A Phase III, randomized, double-blind, placebo-controlled, multi-center clinical trial of oral cladribine in subjects with a first clinical event at high risk of converting to MS
| Status | Finished |
|---|---|
| Effective start/end date | 12/1/08 → 11/30/12 |
Funding
- EMD Serono, Inc.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.